Researchers evaluated the performance of the 2017 EULAR/ACR classification criteria in a cohort of patients with MDA5-associated idiopathic inflammatory myopathy (IIM).
The British Society for Rheumatology developed guidelines for the management of idiopathic inflammatory myopathy among pediatric and adult patients.
The Company is currently evaluating DYN101 in the phase 1/2 UNITE-CNM trial in patients 16 years of age and older with CNM caused by mutations in the MTM1 or DNM2 gene.
Using the ACR/EULAR criteria, researchers studied the population-based incidence, prevalence, and mortality of dermatomyositis in adults.
Shashank Suresh, MD, takes us on a deep dive into the importance of immune-related adverse events, including immune-related myositis, which can be triggered by immune checkpoint inhibitor therapy.
The FDA has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.
In this case-control autopsy series, study researchers evaluated skeletal muscle and myocardial inflammations in patients with severe COVID-19 who died.
Researchers assessed clinical features, muscle biopsy scores, and myositis-specific antibody profiles in juvenile dermatomyositis, and their association with disease outcomes and treatment responses in patients.
Researchers aimed to evaluate the feasibility of studying creatine in juvenile dermatomyositis and to determine the effect of creatine on muscle function and metabolism.
The study authors’ goal was to raise the possibility that some patients with polymyalgia rheumatica and type 2 diabetes mellitus can avoid glucocorticoid treatment.
